The Chemical Data

Sinopia Biosciences

Sinopia Biosciences wins NCI grant to advance LEADS® oncology platform.

Sinopia Biosciences Awarded NCI Grant to Advance LEADS® Drug Discovery Platform for Oncology Sinopia Biosciences, Inc., a biotechnology company advancing novel therapeutics identified using its proprietary LEADS® (LEarn And DiScover) drug discovery platform, today announced it has been awarded a…

Read MoreSinopia Biosciences wins NCI grant to advance LEADS® oncology platform.
NImmune

NImmune to present LANCL2 therapeutic data at IMMUNOLOGY2026.

NImmune Biopharma to Present Novel Mechanistic, Efficacy and Translational Data on LANCL2-Targeting Therapeutics Supporting Significant Pipeline-in-a-Drug Potential at IMMUNOLOGY2026 NImmune Biopharma a private late-stage precision inflammation and immunology (“I&I”) biopharmaceutical company, will present first-ever preclinical and translational data demonstrating the…

Read MoreNImmune to present LANCL2 therapeutic data at IMMUNOLOGY2026.
Arrowhead

Lineage initiates a new cell therapy program targeting corneal endothelial disease.

Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease Lineage Cell Therapeutics, Inc. a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced the expansion of its cell transplant pipeline…

Read MoreLineage initiates a new cell therapy program targeting corneal endothelial disease.
Turn Therapeutics

Turn Therapeutics raises up to $25 million in funding from Avenue Capital Group.

Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…

Read MoreTurn Therapeutics raises up to $25 million in funding from Avenue Capital Group.
BioSolutions

Artis BioSolutions launches a synthetic DNA manufacturing hub in Boston, USA.

Artis BioSolutions Establishes U.S.-based Synthetic DNA Manufacturing Hub in Boston Artis BioSolutions an advanced therapies company dedicated to integrating the specialized technologies, infrastructure, and manufacturing capabilities required to deliver next-generation genetic medicines, today announced the establishment of new synthetic DNA…

Read MoreArtis BioSolutions launches a synthetic DNA manufacturing hub in Boston, USA.

Prothena partners present next-gen Parkinson’s and Alzheimer’s data at AD/PD™ 2026.

Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026 Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner…

Read MoreProthena partners present next-gen Parkinson’s and Alzheimer’s data at AD/PD™ 2026.
Almirall’s

Almirall’s 17th Skin Academy spotlights advances in inflammatory skin diseases and skin cancer.

Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy,…

Read MoreAlmirall’s 17th Skin Academy spotlights advances in inflammatory skin diseases and skin cancer.
Anumana

CPUC conditionally approves RNG contract from Anaergia’s SoCal biomethane facility.

California Public Utilities Commission Conditionally Approves RNG Procurement Contract from Anaergia’s SoCal Biomethane Facility Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG; OTCQX: ANRGF) reports that the California Public Utilities Commission (“CPUC”) has conditionally approved a long-term biomethane procurement contract…

Read MoreCPUC conditionally approves RNG contract from Anaergia’s SoCal biomethane facility.
Novartis

Novartis to acquire Synnovation’s pan-mutant selective PI3Kα inhibitor program.

Novartis to Acquire Synnovation Therapeutics’ Pan-Mutant Selective PI3Kα Inhibitor Program Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology today announced a definitive agreement for Novartis to acquire…

Read MoreNovartis to acquire Synnovation’s pan-mutant selective PI3Kα inhibitor program.